PT  - JOURNAL ARTICLE
AU  - CHARACIEJUS, DAINIUS
AU  - PAŠUKONIENĖ, VITA
AU  - JACOBS, JOHN J.L.
AU  - EIDUKEVIČIUS, RIMANTAS
AU  - JANKEVIČIUS, FELIKSAS
AU  - DOBROVOLSKIENĖ, NERINGA
AU  - MAURICAS, MYKOLAS
AU  - VAN MOORSELAAR, R. JEROEN A.
AU  - DEN OTTER, WILLEM
TI  - Prognostic Significance of Peripheral Blood CD8<em><sup>high</sup></em>CD57<em><sup>+</sup></em> Lymphocytes in Bladder Carcinoma Patients After Intravesical IL-2
DP  - 2011 Feb 01
TA  - Anticancer Research
PG  - 699--703
VI  - 31
IP  - 2
4099  - http://ar.iiarjournals.org/content/31/2/699.short
4100  - http://ar.iiarjournals.org/content/31/2/699.full
SO  - Anticancer Res2011 Feb 01; 31
AB  - Background: The objective of this study was to evaluate the recurrence-preventing effect of intravesical instillations of interleukin-2 (IL-2) in patients with non-muscle-invasive bladder carcinoma. In addition, this study aimed to determine the significance of immune parameters for recurrence-free interval. Patients and Methods: Twenty-six patients with non-muscle-invasive bladder carcinoma were treated with intravesical instillations of IL-2 (Proleukin®, Novartis, formerly Chiron) in doses of 9×106 IU on 5 consecutive days, beginning on the second day after transurethral resection (TUR) of tumours. CD8highCD57+ lymphocytes in peripheral blood were determined before TUR and compared with the recurrence-free interval after treatment. Results: The multivariate analysis showed that CD8highCD57+ lymphocytes had a prognostic significance in combination with number of bladder tumours, prior recurrence rate and age of patients. Conclusion: Peripheral blood CD8highCD57+ lymphocytes have prognostic significance for recurrence-free survival in patients with non-muscle-invasive bladder carcinoma after TUR and intravesical IL-2.